Topical Minocycline for CARP
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age9+
SponsorMedical University of South Carolina
About this trial
This proof-of-concept trial evaluates the efficacy, safety, and patient satisfaction of topical minocycline foam (AMZEEQ®) in patients aged 9 and older with confluent and reticulated papillomatosis (CARP). Participants will apply AMZEEQ® to one side of the body and a topical emollient to the other for 5 weeks, followed by an optional extension period. The study aims to assess whether topical minocycline is a well-tolerated and effective alternative to oral antibiotics.
Eligibility criteria
Qualifiers
Age ≥ 9 years
Clinical diagnosis of CARP
Disqualifiers
Current or recent (within 6 months) use of oral minocycline
Pregnancy or breastfeeding
History of intracranial hypertension, autoimmune disorder, liver/kidney disease
Immunocompromised status
Trial design
Treatments tested in this trial
- Topical Minocycline Foam FXFM244
- Control
Treatment groups
35 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Medical University of South Carolina
Lead sponsor
Journey Medical Corporation
Collaborator
Source ClinicalTrials.gov